메뉴 건너뛰기




Volumn 80, Issue 5, 2008, Pages 369-380

PET/CT in the management of haematological malignancies

Author keywords

Computerised tomography; Haematological malignancy; Lymphoma; Positron emission tomography

Indexed keywords

IMATINIB;

EID: 41849097401     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2008.01051.x     Document Type: Review
Times cited : (43)

References (143)
  • 1
    • 0023120595 scopus 로고
    • Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma
    • Paul R. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. J Nucl Med 1987 28 : 288 92.
    • (1987) J Nucl Med , vol.28 , pp. 288-92
    • Paul, R.1
  • 2
    • 0032548107 scopus 로고    scopus 로고
    • A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease
    • Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998 339 : 1506 14.
    • (1998) N Engl J Med , vol.339 , pp. 1506-14
    • Hasenclever, D.1    Diehl, V.2
  • 3
    • 4444326818 scopus 로고    scopus 로고
    • Follicular lymphoma international prognostic index
    • Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004 104 : 1258 65.
    • (2004) Blood , vol.104 , pp. 1258-65
    • Solal-Celigny, P.1    Roy, P.2    Colombat, P.3
  • 4
    • 0027444652 scopus 로고
    • A predictive model for aggressive non-Hodgkin's lymphoma
    • The International Non-Hodgkin's Lymphoma Prognostic Factors Project.
    • The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993 329 : 987 94.
    • (1993) N Engl J Med , vol.329 , pp. 987-94
  • 5
    • 0030430098 scopus 로고    scopus 로고
    • Magnetic resonance imaging and 67Ga scan versus computed tomography in the staging and in the monitoring of mediastinal malignant lymphoma: A prospective pilot study
    • Bendini M, Zuiani C, Bazzocchi M, Dalpiaz G, Zaja F, Englaro E. Magnetic resonance imaging and 67Ga scan versus computed tomography in the staging and in the monitoring of mediastinal malignant lymphoma: a prospective pilot study. MAGMA 1996 4 : 213 24.
    • (1996) MAGMA , vol.4 , pp. 213-24
    • Bendini, M.1    Zuiani, C.2    Bazzocchi, M.3    Dalpiaz, G.4    Zaja, F.5    Englaro, E.6
  • 7
    • 0031610568 scopus 로고    scopus 로고
    • Cross-sectional imaging with CT and/or MRI of pediatric chest tumors
    • Wyttenbach R, Vock P, Tschappeler H. Cross-sectional imaging with CT and/or MRI of pediatric chest tumors. Eur Radiol 1998 8 : 1040 6.
    • (1998) Eur Radiol , vol.8 , pp. 1040-6
    • Wyttenbach, R.1    Vock, P.2    Tschappeler, H.3
  • 8
    • 0030091284 scopus 로고    scopus 로고
    • Present state and future role of gallium-67 scintigraphy in lymphoma
    • Front D, Israel O. Present state and future role of gallium-67 scintigraphy in lymphoma. J Nucl Med 1996 37 : 530 2.
    • (1996) J Nucl Med , vol.37 , pp. 530-2
    • Front, D.1    Israel, O.2
  • 9
    • 0037083501 scopus 로고    scopus 로고
    • Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma
    • Kostakoglu L, Leonard JP, Kuji I, Coleman M, Vallabhajosula S, Goldsmith SJ. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer 2002 94 : 879 88.
    • (2002) Cancer , vol.94 , pp. 879-88
    • Kostakoglu, L.1    Leonard, J.P.2    Kuji, I.3    Coleman, M.4    Vallabhajosula, S.5    Goldsmith, S.J.6
  • 10
    • 0036124658 scopus 로고    scopus 로고
    • Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma
    • Wirth A, Seymour JF, Hicks RJ, Ware R, Fisher R, Prince M, MacManus MP, Ryan G, Januszewicz H, Wolf M. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med 2002 112 : 262 8.
    • (2002) Am J Med , vol.112 , pp. 262-8
    • Wirth, A.1    Seymour, J.F.2    Hicks, R.J.3    Ware, R.4    Fisher, R.5    Prince, M.6    MacManus, M.P.7    Ryan, G.8    Januszewicz, H.9    Wolf, M.10
  • 11
    • 0038467319 scopus 로고    scopus 로고
    • Gallium-67 scintigraphy: A cornerstone in functional imaging of lymphoma
    • Even-Sapir E, Israel O. Gallium-67 scintigraphy: a cornerstone in functional imaging of lymphoma. Eur J Nucl Med Mol Imaging 2003 30 (Suppl. 1 S65 81.
    • (2003) Eur J Nucl Med Mol Imaging , vol.30 , Issue.1
    • Even-Sapir, E.1    Israel, O.2
  • 12
  • 19
    • 0031869324 scopus 로고    scopus 로고
    • Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: Effectiveness and comparison with computed tomography
    • Stumpe KD, Urbinelli M, Steinert HC, Glanzmann C, Buck A, von Schulthess GK. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998 25 : 721 8.
    • (1998) Eur J Nucl Med , vol.25 , pp. 721-8
    • Stumpe, K.D.1    Urbinelli, M.2    Steinert, H.C.3    Glanzmann, C.4    Buck, A.5    Von Schulthess, G.K.6
  • 20
  • 21
    • 0034023608 scopus 로고    scopus 로고
    • The impact of FDG positron emission tomography imaging on the management of lymphomas
    • Shah N, Hoskin P, McMillan A, Gibson P, Lowe J, wong WL. The impact of FDG positron emission tomography imaging on the management of lymphomas. Br J Radiol 2000 73 : 482 7.
    • (2000) Br J Radiol , vol.73 , pp. 482-7
    • Shah, N.1    Hoskin, P.2    McMillan, A.3    Gibson, P.4    Lowe, J.5    Wong, W.L.6
  • 22
    • 0034909179 scopus 로고    scopus 로고
    • Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma
    • Schoder H, Meta J, Yap C, Ariannejad M, Rao J, Phelps ME, Valk PE, Sayre J, Czernin J. Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med 2001 42 : 1139 43.
    • (2001) J Nucl Med , vol.42 , pp. 1139-43
    • Schoder, H.1    Meta, J.2    Yap, C.3    Ariannejad, M.4    Rao, J.5    Phelps, M.E.6    Valk, P.E.7    Sayre, J.8    Czernin, J.9
  • 23
    • 0032848979 scopus 로고    scopus 로고
    • Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest
    • Bangerter M, Kotzerke J, Griesshammer M, Elsner K, Reske SN, Bergmann L. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncol 1999 38 : 799 804.
    • (1999) Acta Oncol , vol.38 , pp. 799-804
    • Bangerter, M.1    Kotzerke, J.2    Griesshammer, M.3    Elsner, K.4    Reske, S.N.5    Bergmann, L.6
  • 27
    • 0033763664 scopus 로고    scopus 로고
    • 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: Influence on patient management in a single institution
    • Partridge S, Timothy A, O'Doherty MJ, Hain SF, Rankin S, Mikhaeel G. 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. Ann Oncol 2000 11 : 1273 9.
    • (2000) Ann Oncol , vol.11 , pp. 1273-9
    • Partridge, S.1    Timothy, A.2    O'Doherty, M.J.3    Hain, S.F.4    Rankin, S.5    Mikhaeel, G.6
  • 29
    • 0035074636 scopus 로고    scopus 로고
    • Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease
    • Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, Fillet G. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica 2001 86 : 266 73.
    • (2001) Haematologica , vol.86 , pp. 266-73
    • Jerusalem, G.1    Beguin, Y.2    Fassotte, M.F.3    Najjar, F.4    Paulus, P.5    Rigo, P.6    Fillet, G.7
  • 30
    • 0036405370 scopus 로고    scopus 로고
    • Positron emission tomography for the staging of Hodgkin's lymphoma - Increasing the body of evidence in favor of the method
    • Menzel C, Dobert N, Mitrou P, Mose S, Diehl M, Berner U, Grunwald F. Positron emission tomography for the staging of Hodgkin's lymphoma - increasing the body of evidence in favor of the method. Acta Oncol 2002 41 : 430 6.
    • (2002) Acta Oncol , vol.41 , pp. 430-6
    • Menzel, C.1    Dobert, N.2    Mitrou, P.3    Mose, S.4    Diehl, M.5    Berner, U.6    Grunwald, F.7
  • 31
    • 0036938607 scopus 로고    scopus 로고
    • Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease
    • Weihrauch MR, Re D, Bischoff S, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol 2002 81 : 20 5.
    • (2002) Ann Hematol , vol.81 , pp. 20-5
    • Weihrauch, M.R.1    Re, D.2    Bischoff, S.3
  • 32
    • 0037810975 scopus 로고    scopus 로고
    • Applications of positron emission tomography/computed tomography image fusion in clinical positron emission tomography-clinical use, interpretation methods, diagnostic improvements
    • Cohade C, Wahl RL. Applications of positron emission tomography/computed tomography image fusion in clinical positron emission tomography-clinical use, interpretation methods, diagnostic improvements. Semin Nucl Med 2003 33 : 228 37.
    • (2003) Semin Nucl Med , vol.33 , pp. 228-37
    • Cohade, C.1    Wahl, R.L.2
  • 33
    • 10744230082 scopus 로고    scopus 로고
    • Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma
    • Naumann R, Beuthien-Baumann B, Reiss A, et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer 2004 90 : 620 5.
    • (2004) Br J Cancer , vol.90 , pp. 620-5
    • Naumann, R.1    Beuthien-Baumann, B.2    Reiss, A.3
  • 36
    • 40849147717 scopus 로고    scopus 로고
    • Positron emission tomography in the staging of patients with Hodgkin's lymphoma. a prospective multicentric study by the Intergruppo Italiano Linfomi
    • Rigacci L, Vitolo U, Nassi L, et al. Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi. Ann Hematol 2007 86 : 897 903.
    • (2007) Ann Hematol , vol.86 , pp. 897-903
    • Rigacci, L.1    Vitolo, U.2    Nassi, L.3
  • 38
    • 0035281784 scopus 로고    scopus 로고
    • 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. a bicenter trial
    • Buchmann I, Reinhardt M, Elsner K, et al. 2-(fluorine-18)fluoro-2-deoxy- D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 2001 91 : 889 99.
    • (2001) Cancer , vol.91 , pp. 889-99
    • Buchmann, I.1    Reinhardt, M.2    Elsner, K.3
  • 40
    • 23044475707 scopus 로고    scopus 로고
    • 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: A meta-analysis
    • Pakos EE, Fotopoulos AD, Ioannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 2005 46 : 958 63.
    • (2005) J Nucl Med , vol.46 , pp. 958-63
    • Pakos, E.E.1    Fotopoulos, A.D.2    Ioannidis, J.P.3
  • 41
    • 0032854418 scopus 로고    scopus 로고
    • Positron emission tomography in patients with primary CNS lymphomas
    • Roelcke U, Leenders KL. Positron emission tomography in patients with primary CNS lymphomas. J Neurooncol 1999 43 : 231 6.
    • (1999) J Neurooncol , vol.43 , pp. 231-6
    • Roelcke, U.1    Leenders, K.L.2
  • 42
    • 0037371152 scopus 로고    scopus 로고
    • 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) for assessment of enteropathy-type T cell lymphoma
    • Hoffmann M, Vogelsang H, Kletter K, Zettinig G, Chott A, Raderer M. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) for assessment of enteropathy-type T cell lymphoma. Gut 2003 52 : 347 51.
    • (2003) Gut , vol.52 , pp. 347-51
    • Hoffmann, M.1    Vogelsang, H.2    Kletter, K.3    Zettinig, G.4    Chott, A.5    Raderer, M.6
  • 44
    • 0037974889 scopus 로고    scopus 로고
    • 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma
    • Hoffmann M, Kletter K, Becherer A, Jager U, Chott A, Raderer M. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology 2003 64 : 336 40.
    • (2003) Oncology , vol.64 , pp. 336-40
    • Hoffmann, M.1    Kletter, K.2    Becherer, A.3    Jager, U.4    Chott, A.5    Raderer, M.6
  • 45
    • 2342529042 scopus 로고    scopus 로고
    • 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) does not visualize follicular lymphoma of the duodenum
    • Hoffmann M, Chott A, Puspok A, Jager U, Kletter K, Raderer M. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) does not visualize follicular lymphoma of the duodenum. Ann Hematol 2004 83 : 276 8.
    • (2004) Ann Hematol , vol.83 , pp. 276-8
    • Hoffmann, M.1    Chott, A.2    Puspok, A.3    Jager, U.4    Kletter, K.5    Raderer, M.6
  • 46
    • 33646181100 scopus 로고    scopus 로고
    • 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading
    • Wohrer S, Jaeger U, Kletter K, Becherer A, Hauswirth A, Turetschek K, Raderer M, Hoffmann M. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Ann Oncol 2006 17 : 780 4.
    • (2006) Ann Oncol , vol.17 , pp. 780-4
    • Wohrer, S.1    Jaeger, U.2    Kletter, K.3    Becherer, A.4    Hauswirth, A.5    Turetschek, K.6    Raderer, M.7    Hoffmann, M.8
  • 47
    • 0034948354 scopus 로고    scopus 로고
    • Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL)
    • Jerusalem G, Beguin Y, Najjar F, Hustinx R, Fassotte MF, Rigo P, Fillet G. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol 2001 12 : 825 30.
    • (2001) Ann Oncol , vol.12 , pp. 825-30
    • Jerusalem, G.1    Beguin, Y.2    Najjar, F.3    Hustinx, R.4    Fassotte, M.F.5    Rigo, P.6    Fillet, G.7
  • 48
    • 0038681075 scopus 로고    scopus 로고
    • Utility of FDG-PET scanning in lymphoma by WHO classification
    • Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003 101 : 3875 6.
    • (2003) Blood , vol.101 , pp. 3875-6
    • Elstrom, R.1    Guan, L.2    Baker, G.3
  • 49
    • 16244400833 scopus 로고    scopus 로고
    • FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: A report of 42 cases
    • Beal KP, Yeung HW, Yahalom J. FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases. Ann Oncol 2005 16 : 473 80.
    • (2005) Ann Oncol , vol.16 , pp. 473-80
    • Beal, K.P.1    Yeung, H.W.2    Yahalom, J.3
  • 50
  • 52
    • 0034790793 scopus 로고    scopus 로고
    • Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL)
    • Najjar F, Hustinx R, Jerusalem G, Fillet G, Rigo P. Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL). Cancer Biother Radiopharm 2001 16 : 297 304.
    • (2001) Cancer Biother Radiopharm , vol.16 , pp. 297-304
    • Najjar, F.1    Hustinx, R.2    Jerusalem, G.3    Fillet, G.4    Rigo, P.5
  • 53
    • 23044469098 scopus 로고    scopus 로고
    • Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma
    • Schoder H, Noy A, Gonen M, Weng L, Green D, Erdi YE, Larson SM, Yeung HW. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 2005 23 : 4643 51.
    • (2005) J Clin Oncol , vol.23 , pp. 4643-51
    • Schoder, H.1    Noy, A.2    Gonen, M.3    Weng, L.4    Green, D.5    Erdi, Y.E.6    Larson, S.M.7    Yeung, H.W.8
  • 54
    • 10244221207 scopus 로고    scopus 로고
    • Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma
    • Allen-Auerbach M, Quon A, Weber WA, Obrzut S, Crawford T, Silverman DH, Ratib O, Phelps ME, Czernin J. Comparison between 2-deoxy-2-[18F]fluoro-D- glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. Mol Imaging Biol 2004 6 : 411 6.
    • (2004) Mol Imaging Biol , vol.6 , pp. 411-6
    • Allen-Auerbach, M.1    Quon, A.2    Weber, W.A.3    Obrzut, S.4    Crawford, T.5    Silverman, D.H.6    Ratib, O.7    Phelps, M.E.8    Czernin, J.9
  • 56
    • 0026942042 scopus 로고
    • Prognostic factors in Hodgkin's disease
    • Specht L. Prognostic factors in Hodgkin's disease. Dan Med Bull 1992 39 : 409 22.
    • (1992) Dan Med Bull , vol.39 , pp. 409-22
    • Specht, L.1
  • 58
    • 0038128305 scopus 로고    scopus 로고
    • Assessment of response to therapy using conventional imaging
    • Rankin SC. Assessment of response to therapy using conventional imaging. Eur J Nucl Med Mol Imaging 2003 30 (Suppl 1 S56 64.
    • (2003) Eur J Nucl Med Mol Imaging , vol.30 , Issue.1
    • Rankin, S.C.1
  • 60
    • 0002278336 scopus 로고    scopus 로고
    • Clinical Evaluation and Staging
    • In: Mauch, P., Armitage, J.O., Diehl, V., Hoppe, R., Weiss, L.M., eds. Philadelphia: Lippincott Williams and Wilkins
    • Gupta RK, Gospodarowicz MK, Lister TA. Clinical Evaluation and Staging. In : Mauch P, Armitage JO, Diehl V, Hoppe R, Weiss LM, eds. Hodgkin's Disease. Philadelphia : Lippincott Williams and Wilkins, 1999 : 223 40.
    • (1999) Hodgkin's Disease. , pp. 223-40
    • Gupta, R.K.1    Gospodarowicz, M.K.2    Lister, T.A.3
  • 61
    • 0023899907 scopus 로고
    • Residual mass in lymphoma may not be residual disease
    • Canellos GP. Residual mass in lymphoma may not be residual disease. J Clin Oncol 1988 6 : 931 3.
    • (1988) J Clin Oncol , vol.6 , pp. 931-3
    • Canellos, G.P.1
  • 62
    • 0033624050 scopus 로고    scopus 로고
    • Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma
    • Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, Fillet G. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica 2000 85 : 613 8.
    • (2000) Haematologica , vol.85 , pp. 613-8
    • Jerusalem, G.1    Beguin, Y.2    Fassotte, M.F.3    Najjar, F.4    Paulus, P.5    Rigo, P.6    Fillet, G.7
  • 63
    • 0034485716 scopus 로고    scopus 로고
    • 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT
    • Mikhaeel NG, Timothy AR, O'Doherty MJ, Hain S, Maisey MN. 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT. Leuk Lymphoma 2000 6 : 543 53.
    • (2000) Leuk Lymphoma , vol.6 , pp. 543-53
    • Mikhaeel, N.G.1    Timothy, A.R.2    O'Doherty, M.J.3    Hain, S.4    Maisey, M.N.5
  • 66
    • 0036327331 scopus 로고    scopus 로고
    • PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease
    • Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002 43 : 1018 27.
    • (2002) J Nucl Med , vol.43 , pp. 1018-27
    • Kostakoglu, L.1    Coleman, M.2    Leonard, J.P.3    Kuji, I.4    Zoe, H.5    Goldsmith, S.J.6
  • 68
    • 24044553298 scopus 로고    scopus 로고
    • FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma
    • Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005 16 : 1514 23.
    • (2005) Ann Oncol , vol.16 , pp. 1514-23
    • Mikhaeel, N.G.1    Hutchings, M.2    Fields, P.A.3    O'Doherty, M.J.4    Timothy, A.R.5
  • 69
    • 23744498053 scopus 로고    scopus 로고
    • [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: An early prognostic tool for predicting patient outcome
    • Haioun C, Itti E, Rahmouni A, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005 106 : 1376 81.
    • (2005) Blood , vol.106 , pp. 1376-81
    • Haioun, C.1    Itti, E.2    Rahmouni, A.3
  • 70
    • 25444437438 scopus 로고    scopus 로고
    • Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma
    • Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005 16 : 1160 8.
    • (2005) Ann Oncol , vol.16 , pp. 1160-8
    • Hutchings, M.1    Mikhaeel, N.G.2    Fields, P.A.3    Nunan, T.4    Timothy, A.R.5
  • 71
    • 30144432586 scopus 로고    scopus 로고
    • FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
    • Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006 107 : 52 9.
    • (2006) Blood , vol.107 , pp. 52-9
    • Hutchings, M.1    Loft, A.2    Hansen, M.3
  • 72
    • 33747873263 scopus 로고    scopus 로고
    • Early positron emission tomography (PET) restaging: A predictive final response in Hodgkin's disease patients
    • Zinzani PL, Tani M, Fanti S, et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol 2006 17 : 1296 300.
    • (2006) Ann Oncol , vol.17 , pp. 1296-300
    • Zinzani, P.L.1    Tani, M.2    Fanti, S.3
  • 73
    • 33645998113 scopus 로고    scopus 로고
    • The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease
    • Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006 91 : 475 81.
    • (2006) Haematologica , vol.91 , pp. 475-81
    • Gallamini, A.1    Rigacci, L.2    Merli, F.3
  • 74
    • 34548486030 scopus 로고    scopus 로고
    • Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study
    • Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007 25 : 3746 52.
    • (2007) J Clin Oncol , vol.25 , pp. 3746-52
    • Gallamini, A.1    Hutchings, M.2    Rigacci, L.3
  • 75
    • 29244432478 scopus 로고    scopus 로고
    • Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes?
    • Girinsky T, Pichenot C, Beaudre A, Ghalibafian M, Lefkopoulos D. Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes? Int J Radiat Oncol Biol Phys 2006 64 : 218 26.
    • (2006) Int J Radiat Oncol Biol Phys , vol.64 , pp. 218-26
    • Girinsky, T.1    Pichenot, C.2    Beaudre, A.3    Ghalibafian, M.4    Lefkopoulos, D.5
  • 77
    • 0031934031 scopus 로고    scopus 로고
    • Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: A meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group
    • Specht L, Gray RG, Clarke MJ, Peto R. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group. J Clin Oncol 1998 16 : 830 43.
    • (1998) J Clin Oncol , vol.16 , pp. 830-43
    • Specht, L.1    Gray, R.G.2    Clarke, M.J.3    Peto, R.4
  • 78
    • 21044443290 scopus 로고    scopus 로고
    • Transformation in the use of radiation therapy of Hodgkin lymphoma: New concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT)
    • Yahalom J. Transformation in the use of radiation therapy of Hodgkin lymphoma: new concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT). Eur J Haematol Suppl 2005 66 : 90 7.
    • (2005) Eur J Haematol Suppl , vol.66 , pp. 90-7
    • Yahalom, J.1
  • 79
    • 36349025232 scopus 로고    scopus 로고
    • Is FDG-PET scan in patients with early stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy concept and dose painting?
    • Girinsky T, Ghalibafian M, Bonniaud G, Bayla A, Magne N, Ferreira I, Lumbroso J. Is FDG-PET scan in patients with early stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy concept and dose painting? Radiother Oncol 2007 85 : 178 86.
    • (2007) Radiother Oncol , vol.85 , pp. 178-86
    • Girinsky, T.1    Ghalibafian, M.2    Bonniaud, G.3    Bayla, A.4    Magne, N.5    Ferreira, I.6    Lumbroso, J.7
  • 80
    • 10044273157 scopus 로고    scopus 로고
    • Is there any future in radiotherapy planning without the use of PET: Unraveling the myth
    • Gregoire V. Is there any future in radiotherapy planning without the use of PET: unraveling the myth. Radiother Oncol 2004 73 : 261 3.
    • (2004) Radiother Oncol , vol.73 , pp. 261-3
    • Gregoire, V.1
  • 82
    • 34250698039 scopus 로고    scopus 로고
    • 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas
    • Specht L. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas. Semin Radiat Oncol 2007 17 : 190 7.
    • (2007) Semin Radiat Oncol , vol.17 , pp. 190-7
    • Specht, L.1
  • 86
    • 33846965941 scopus 로고    scopus 로고
    • Clinical impact of FDG-PET/CT in the planning of radiotherapy for early stage Hodgkin lymphoma
    • Hutchings M, Berthelsen AK, Loft A, Hansen M, Specht L. Clinical impact of FDG-PET/CT in the planning of radiotherapy for early stage Hodgkin lymphoma. Eur J Haematol 2007 78 : 206 12.
    • (2007) Eur J Haematol , vol.78 , pp. 206-12
    • Hutchings, M.1    Berthelsen, A.K.2    Loft, A.3    Hansen, M.4    Specht, L.5
  • 87
    • 1642335524 scopus 로고    scopus 로고
    • Positron emission tomography in pediatric radiation oncology: Integration in the treatment-planning process
    • Krasin MJ, Hudson MM, Kaste SC. Positron emission tomography in pediatric radiation oncology: integration in the treatment-planning process. Pediatr Radiol 2004 34 : 214 21.
    • (2004) Pediatr Radiol , vol.34 , pp. 214-21
    • Krasin, M.J.1    Hudson, M.M.2    Kaste, S.C.3
  • 88
    • 0042449063 scopus 로고    scopus 로고
    • Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group
    • Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999 17 : 1244.
    • (1999) J Clin Oncol , vol.17 , pp. 1244
    • Cheson, B.D.1    Horning, S.J.2    Coiffier, B.3
  • 89
  • 90
    • 34247855900 scopus 로고    scopus 로고
    • PET and PET/CT for response evaluation in lymphoma: Current practice and developments
    • Brepoels L, Stroobants S, Verhoef G. PET and PET/CT for response evaluation in lymphoma: current practice and developments. Leuk Lymphoma 2007 48 : 270 82.
    • (2007) Leuk Lymphoma , vol.48 , pp. 270-82
    • Brepoels, L.1    Stroobants, S.2    Verhoef, G.3
  • 91
    • 0031742182 scopus 로고    scopus 로고
    • Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma
    • Cremerius U, Fabry U, Neuerburg J, Zimny M, Osieka R, Buell U. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun 1998 19 : 1055 63.
    • (1998) Nucl Med Commun , vol.19 , pp. 1055-63
    • Cremerius, U.1    Fabry, U.2    Neuerburg, J.3    Zimny, M.4    Osieka, R.5    Buell, U.6
  • 92
    • 0030978419 scopus 로고    scopus 로고
    • Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma
    • de Wit M, Bumann D, Beyer W, Herbst K, Clausen M, Hossfeld DK. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol 1997 8 (Suppl. 1 57 60.
    • (1997) Ann Oncol , vol.8 , Issue.1 , pp. 57-60
    • De Wit, M.1    Bumann, D.2    Beyer, W.3    Herbst, K.4    Clausen, M.5    Hossfeld, D.K.6
  • 93
    • 0034746308 scopus 로고    scopus 로고
    • 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma
    • de Wit M, Bohuslavizki KH, Buchert R, Bumann D, Clausen M, Hossfeld DK. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 2001 12 : 29 37.
    • (2001) Ann Oncol , vol.12 , pp. 29-37
    • De Wit, M.1    Bohuslavizki, K.H.2    Buchert, R.3    Bumann, D.4    Clausen, M.5    Hossfeld, D.K.6
  • 96
    • 0141557973 scopus 로고    scopus 로고
    • Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation
    • Guay C, Lepine M, Verreault J, Benard F. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. J Nucl Med 2003 44 : 1225 31.
    • (2003) J Nucl Med , vol.44 , pp. 1225-31
    • Guay, C.1    Lepine, M.2    Verreault, J.3    Benard, F.4
  • 97
    • 0033566341 scopus 로고    scopus 로고
    • Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging
    • Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, Fillet G. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999 94 : 429 33.
    • (1999) Blood , vol.94 , pp. 429-33
    • Jerusalem, G.1    Beguin, Y.2    Fassotte, M.F.3    Najjar, F.4    Paulus, P.5    Rigo, P.6    Fillet, G.7
  • 99
    • 0035104060 scopus 로고    scopus 로고
    • Clinical relevance of positron emission tomography (PET) in treatment control and relapse of Hodgkin's disease
    • Lang O, Bihl H, Hultenschmidt B, Sautter-Bihl ML. Clinical relevance of positron emission tomography (PET) in treatment control and relapse of Hodgkin's disease. Strahlenther Onkol 2001 177 : 138 44.
    • (2001) Strahlenther Onkol , vol.177 , pp. 138-44
    • Lang, O.1    Bihl, H.2    Hultenschmidt, B.3    Sautter-Bihl, M.L.4
  • 101
    • 0033621989 scopus 로고    scopus 로고
    • Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses?
    • Maisey NR, Hill ME, Webb A, Cunningham D, Flux GD, Padhani A, Ott RJ, Norman A, Bishop L. Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses? Eur J Cancer 2000 36 : 200 6.
    • (2000) Eur J Cancer , vol.36 , pp. 200-6
    • Maisey, N.R.1    Hill, M.E.2    Webb, A.3    Cunningham, D.4    Flux, G.D.5    Padhani, A.6    Ott, R.J.7    Norman, A.8    Bishop, L.9
  • 102
    • 0033996693 scopus 로고    scopus 로고
    • 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas
    • Mikhaeel NG, Timothy AR, Hain SF, O'Doherty MJ. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol 2000 11 (Suppl. 1 147 50.
    • (2000) Ann Oncol , vol.11 , Issue.1 , pp. 147-50
    • Mikhaeel, N.G.1    Timothy, A.R.2    Hain, S.F.3    O'Doherty, M.J.4
  • 103
    • 0035676671 scopus 로고    scopus 로고
    • Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma
    • Naumann R, Vaic A, Beuthien-Baumann B, Bredow J, Kropp J, Kittner T, Franke WG, Ehninger G. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 2001 115 : 793 800.
    • (2001) Br J Haematol , vol.115 , pp. 793-800
    • Naumann, R.1    Vaic, A.2    Beuthien-Baumann, B.3    Bredow, J.4    Kropp, J.5    Kittner, T.6    Franke, W.G.7    Ehninger, G.8
  • 105
    • 33645011656 scopus 로고    scopus 로고
    • Quantitative CT analysis for assessing response in lymphoma (Cheson's criteria)
    • Spec No A:
    • Rahmouni A, Luciani A, Itti E. Quantitative CT analysis for assessing response in lymphoma (Cheson's criteria). Cancer Imaging 2005 5 Spec No A : S102 6.
    • (2005) Cancer Imaging , vol.5
    • Rahmouni, A.1    Luciani, A.2    Itti, E.3
  • 106
    • 24044475903 scopus 로고    scopus 로고
    • Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: When do we really need FDG-PET?
    • Reinhardt MJ, Herkel C, Altehoefer C, Finke J, Moser E. Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET? Ann Oncol 2005 16 : 1524 9.
    • (2005) Ann Oncol , vol.16 , pp. 1524-9
    • Reinhardt, M.J.1    Herkel, C.2    Altehoefer, C.3    Finke, J.4    Moser, E.5
  • 107
    • 0038409977 scopus 로고    scopus 로고
    • PET and restaging of malignant lymphoma including residual masses and relapse
    • Reske SN. PET and restaging of malignant lymphoma including residual masses and relapse. Eur J Nucl Med Mol Imaging 2003 30 (Suppl. 1 S89 96.
    • (2003) Eur J Nucl Med Mol Imaging , vol.30 , Issue.1
    • Reske, S.N.1
  • 108
    • 27744560443 scopus 로고    scopus 로고
    • 18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: Long-term results
    • Rigacci L, Castagnoli A, Dini C, et al. 18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: long-term results. Oncol Rep 2005 14 : 1209 14.
    • (2005) Oncol Rep , vol.14 , pp. 1209-14
    • Rigacci, L.1    Castagnoli, A.2    Dini, C.3
  • 109
    • 0035725231 scopus 로고    scopus 로고
    • Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?
    • Spaepen K, Stroobants S, Dupont P, Thomas J, Vandenberghe P, Balzarini J, Wolf-Peeters C, Mortelmans L, Verhoef G. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 2001 115 : 272 8.
    • (2001) Br J Haematol , vol.115 , pp. 272-8
    • Spaepen, K.1    Stroobants, S.2    Dupont, P.3    Thomas, J.4    Vandenberghe, P.5    Balzarini, J.6    Wolf-Peeters, C.7    Mortelmans, L.8    Verhoef, G.9
  • 110
    • 0035863387 scopus 로고    scopus 로고
    • Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
    • Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001 19 : 414 9.
    • (2001) J Clin Oncol , vol.19 , pp. 414-9
    • Spaepen, K.1    Stroobants, S.2    Dupont, P.3
  • 111
    • 19244367762 scopus 로고    scopus 로고
    • Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease
    • Weihrauch MR, Re D, Scheidhauer K, et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001 98 : 2930 4.
    • (2001) Blood , vol.98 , pp. 2930-4
    • Weihrauch, M.R.1    Re, D.2    Scheidhauer, K.3
  • 112
    • 33645999354 scopus 로고    scopus 로고
    • 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: A systematic review
    • Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, Hooft L, Riphagen II, Huijgens PC. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica 2006 91 : 522 9.
    • (2006) Haematologica , vol.91 , pp. 522-9
    • Zijlstra, J.M.1    Lindauer-Van Der Werf, G.2    Hoekstra, O.S.3    Hooft, L.4    Riphagen, I.I.5    Huijgens, P.C.6
  • 113
    • 23044497490 scopus 로고    scopus 로고
    • Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography
    • Juweid ME, Wiseman GA, Vose JM, et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 2005 23 : 4652 61.
    • (2005) J Clin Oncol , vol.23 , pp. 4652-61
    • Juweid, M.E.1    Wiseman, G.A.2    Vose, J.M.3
  • 114
    • 33947496614 scopus 로고    scopus 로고
    • Revised Response Criteria for Malignant Lymphoma
    • Cheson BD, Pfistner B, Juweid ME, et al. Revised Response Criteria for Malignant Lymphoma. J Clin Oncol 2007 25 : 579 86.
    • (2007) J Clin Oncol , vol.25 , pp. 579-86
    • Cheson, B.D.1    Pfistner, B.2    Juweid, M.E.3
  • 115
    • 33947512956 scopus 로고    scopus 로고
    • Use of positron emission tomography (PET) for response assessment of lymphoma: Consensus of the Imaging Subcommittee of the International Harmonization Project in Lymphoma
    • Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography (PET) for response assessment of lymphoma: consensus of the Imaging Subcommittee of the International Harmonization Project in Lymphoma. J Clin Oncol 2007 25 : 571 8.
    • (2007) J Clin Oncol , vol.25 , pp. 571-8
    • Juweid, M.E.1    Stroobants, S.2    Hoekstra, O.S.3
  • 118
    • 34548575042 scopus 로고    scopus 로고
    • Omitting radiotherapy after attaining FDG PET-negative status following chemotherapy alone for Hodgkin lymphoma: A randomized study caveat
    • Yahalom J. Omitting radiotherapy after attaining FDG PET-negative status following chemotherapy alone for Hodgkin lymphoma: a randomized study caveat. Leuk Lymphoma 2007 48 : 1667 9.
    • (2007) Leuk Lymphoma , vol.48 , pp. 1667-9
    • Yahalom, J.1
  • 119
    • 34548546788 scopus 로고    scopus 로고
    • Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans
    • Picardi M, De Renzo A, Pane F, Nicolai E, Pacelli R, Salvatore M, Rotoli B. Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma 2007 48 : 1721 7.
    • (2007) Leuk Lymphoma , vol.48 , pp. 1721-7
    • Picardi, M.1    De Renzo, A.2    Pane, F.3    Nicolai, E.4    Pacelli, R.5    Salvatore, M.6    Rotoli, B.7
  • 120
    • 0037250291 scopus 로고    scopus 로고
    • Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease
    • Jerusalem G, Beguin Y, Fassotte MF, Belhocine T, Hustinx R, Rigo P, Fillet G. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 2003 14 : 123 30.
    • (2003) Ann Oncol , vol.14 , pp. 123-30
    • Jerusalem, G.1    Beguin, Y.2    Fassotte, M.F.3    Belhocine, T.4    Hustinx, R.5    Rigo, P.6    Fillet, G.7
  • 121
    • 34347253223 scopus 로고    scopus 로고
    • Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma
    • Zinzani PL, Tani M, Trisolini R, et al. Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. Haematologica 2007 92 : 771 7.
    • (2007) Haematologica , vol.92 , pp. 771-7
    • Zinzani, P.L.1    Tani, M.2    Trisolini, R.3
  • 122
    • 0033890745 scopus 로고    scopus 로고
    • Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol - A groupe d'Etude des lymphomes de l'Adulte study
    • Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol - a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 2000 18 : 3025 30.
    • (2000) J Clin Oncol , vol.18 , pp. 3025-30
    • Haioun, C.1    Lepage, E.2    Gisselbrecht, C.3
  • 123
    • 0031962299 scopus 로고    scopus 로고
    • Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: Value of augmented preparative regimens - A Southwest Oncology Group trial
    • Stiff PJ, Dahlberg S, Forman SJ, McCall AR, Horning SJ, Nademanee AP, Blume KG, LeBlanc M, Fisher RI. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens - a Southwest Oncology Group trial. J Clin Oncol 1998 16 : 48 55.
    • (1998) J Clin Oncol , vol.16 , pp. 48-55
    • Stiff, P.J.1    Dahlberg, S.2    Forman, S.J.3    McCall, A.R.4    Horning, S.J.5    Nademanee, A.P.6    Blume, K.G.7    Leblanc, M.8    Fisher, R.I.9
  • 124
    • 0036169215 scopus 로고    scopus 로고
    • Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation
    • Becherer A, Mitterbauer M, Jaeger U, Kalhs P, Greinix HT, Karanikas G, Potzi C, Raderer M, Dudczak R, Kletter K. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia 2002 16 : 260 7.
    • (2002) Leukemia , vol.16 , pp. 260-7
    • Becherer, A.1    Mitterbauer, M.2    Jaeger, U.3    Kalhs, P.4    Greinix, H.T.5    Karanikas, G.6    Potzi, C.7    Raderer, M.8    Dudczak, R.9    Kletter, K.10
  • 125
    • 0036050297 scopus 로고    scopus 로고
    • Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma
    • Cremerius U, Fabry U, Wildberger JE, Zimny M, Reinartz P, Nowak B, Schaefer W, Buell U, Osieka R. Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 2002 30 : 103 11.
    • (2002) Bone Marrow Transplant , vol.30 , pp. 103-11
    • Cremerius, U.1    Fabry, U.2    Wildberger, J.E.3    Zimny, M.4    Reinartz, P.5    Nowak, B.6    Schaefer, W.7    Buell, U.8    Osieka, R.9
  • 126
    • 0037630376 scopus 로고    scopus 로고
    • Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation
    • Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003 102 : 53 9.
    • (2003) Blood , vol.102 , pp. 53-9
    • Spaepen, K.1    Stroobants, S.2    Dupont, P.3
  • 127
    • 0042231122 scopus 로고    scopus 로고
    • Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation
    • Filmont JE, Czernin J, Yap C, Silverman DH, Quon A, Phelps ME, Emmanouilides C. Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Chest 2003 124 : 608 13.
    • (2003) Chest , vol.124 , pp. 608-13
    • Filmont, J.E.1    Czernin, J.2    Yap, C.3    Silverman, D.H.4    Quon, A.5    Phelps, M.E.6    Emmanouilides, C.7
  • 129
    • 0036948617 scopus 로고    scopus 로고
    • Diagnostic utility of FDG PET in multiple myeloma
    • Jadvar H, Conti PS. Diagnostic utility of FDG PET in multiple myeloma. Skeletal Radiol 2002 31 : 690 4.
    • (2002) Skeletal Radiol , vol.31 , pp. 690-4
    • Jadvar, H.1    Conti, P.S.2
  • 134
    • 33846916461 scopus 로고    scopus 로고
    • A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma
    • Zamagni E, Nanni C, Patriarca F, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica 2007 92 : 50 5.
    • (2007) Haematologica , vol.92 , pp. 50-5
    • Zamagni, E.1    Nanni, C.2    Patriarca, F.3
  • 135
    • 33746515610 scopus 로고    scopus 로고
    • The role of anatomic and functional staging in myeloma: Description of Durie/Salmon plus staging system
    • Durie BG. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer 2006 42 : 1539 43.
    • (2006) Eur J Cancer , vol.42 , pp. 1539-43
    • Durie, B.G.1
  • 138
    • 0035130893 scopus 로고    scopus 로고
    • Technetium-99m-sestamibi scintigraphy in multiple myeloma and related gammopathies: A useful tool for the identification and follow-up of myeloma bone disease
    • Balleari E, Villa G, Garre S, et al. Technetium-99m-sestamibi scintigraphy in multiple myeloma and related gammopathies: a useful tool for the identification and follow-up of myeloma bone disease. Haematologica 2001 86 : 78 84.
    • (2001) Haematologica , vol.86 , pp. 78-84
    • Balleari, E.1    Villa, G.2    Garre, S.3
  • 139
    • 28444462083 scopus 로고    scopus 로고
    • Comparison of Tc-99m sestamibi and F-18 FDG-PET in the assessment of multiple myeloma
    • Hung GU, Tsai CC, Tsai SC, Lin WY. Comparison of Tc-99m sestamibi and F-18 FDG-PET in the assessment of multiple myeloma. Anticancer Res 2005 25 : 4737 41.
    • (2005) Anticancer Res , vol.25 , pp. 4737-41
    • Hung, G.U.1    Tsai, C.C.2    Tsai, S.C.3    Lin, W.Y.4
  • 140
    • 24944582938 scopus 로고    scopus 로고
    • BaselinTc99-MIBI scanning predicts survival in multiple myeloma and helps to differentiate this disease from monoclonal gammopathy of unknown significance
    • Martin MG, Romero Colas MS, Dourdil Sahun MV, Olave P, Alba PR, Banzo JB. BaselinTc99-MIBI scanning predicts survival in multiple myeloma and helps to differentiate this disease from monoclonal gammopathy of unknown significance. Haematologica 2005 90 : 1141 3.
    • (2005) Haematologica , vol.90 , pp. 1141-3
    • Martin, M.G.1    Romero Colas, M.S.2    Dourdil Sahun, M.V.3    Olave, P.4    Alba, P.R.5    Banzo, J.B.6
  • 141
    • 0742269486 scopus 로고    scopus 로고
    • A comparison of fluorine-18 fluoro-deoxyglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma
    • Mileshkin L, Blum R, Seymour JF, Patrikeos A, Hicks RJ, Prince HM. A comparison of fluorine-18 fluoro-deoxyglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma. Eur J Haematol 2004 72 : 32 7.
    • (2004) Eur J Haematol , vol.72 , pp. 32-7
    • Mileshkin, L.1    Blum, R.2    Seymour, J.F.3    Patrikeos, A.4    Hicks, R.J.5    Prince, H.M.6
  • 143
    • 13644264936 scopus 로고    scopus 로고
    • Diffuse bone marrow accumulation of FDG in a patient with chronic myeloid leukemia mimics hematopoietic cytokine-mediated FDG uptake on positron emission tomography
    • Takalkar A, Yu JQ, Kumar R, Xiu Y, Alavi A, Zhuang H. Diffuse bone marrow accumulation of FDG in a patient with chronic myeloid leukemia mimics hematopoietic cytokine-mediated FDG uptake on positron emission tomography. Clin Nucl Med 2004 29 : 637 9.
    • (2004) Clin Nucl Med , vol.29 , pp. 637-9
    • Takalkar, A.1    Yu, J.Q.2    Kumar, R.3    Xiu, Y.4    Alavi, A.5    Zhuang, H.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.